A 45.5% mitigation rate ignited—is XNCR up 16% in one day enough?

NEXT PICK · Market Insights

A 45.5% mitigation rate ignited—is XNCR up 16% in one day enough?

Monday, October 26, 2026

At Monday's close, Xencor ($XNCR) was at $29.18, surging 15.89% in a single day, with trading volume reaching 6.6 times the three-month daily average. During the session, it once reached $33.6, with a market value above $2.17 billion, while the company's revenue for the past full fiscal year was only $125.6 million.

What sparked the event was not the financial report or the M&A, but a brief presentation at Sunday's ESMO conference in Madrid: the renal cancer bispecific antibody XmAb819 delivered a confirmed objective response rate of 45.5% in the 400 mcg/kg dose group, with an estimated 6-month progression-free survival of 82%. The company immediately announced it as the recommended dose for a late-stage study.

But it is also important not to overlook that the market has pulled back significantly between the intraday peak and closing price, and **funds began to cash out on the same day as the frenzy. Can a set of early data from only a dozen assessable patients really support a biotech company that has been losing money for years to a new level?

Latest price $29.18 ▲ +15.89%

Quantity ratio 6.6 times ▲ Compared to the 3-month daily average

Confirm the remission rate 45.5% ▲ 400 mcg/kg group

Antibody engineers who started out selling "parts" are now learning to build complete vehicles

Xencor is an engineered antibody company focused on oncology and autoimmune diseases. Its greatest value is not a single drug, but a reusable "antibody modification toolbox": XmAb Fc technology, Proteins by Design protein design system, and a complete bispecific antibody platform.

The company's 10-K disclosed commercialization portfolio includes two prominent names: Ultomiris, covering aHUS, gMG, and NMOSD, and Monjuvi, designed for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). But be clear, these two drugs are sold by partners; Xencor mainly receives royalties paid by Alexion and Incyte, not from its own drug sales.

It's like an engineering company supplying core engine components to top automakers—if the car sells well, it gets a share; But who the manufacturer is and how it sets prices is not up to it. Because of this, Xencor's revenue naturally carries the mark of "cooperation rhythm." FY 2025 revenue was $125.6 million, up 13.7% year-on-year, but in Q1 2026, it plummeted to $4.5 million, down 86.2% year-on-year.

Q2 revenue rebounded to $51.2 million, up 17.4% year-over-year. Breaking it down, this includes $27.6 million in franchise income recognized in Alexion settlements and $10 million in regulatory milestones paid by Zenas BioPharma, totaling $55.7 million in the first half, still down 27.0% year-on-year.

The pipeline contains at least 16 antibodies or candidate drugs, spanning ovarian cancer, renal cell carcinoma, prostate cancer, gastric cancer, DLBCL, inflammatory bowel disease, rheumatoid arthritis, and even HIV and chronic hepatitis D; XmAb819, XmAb808, Xaluritamig, Plamotamab, JNJ-9401 all use bispecific antibody technology, and external collaborations from Novartis, Johnson & Johnson, and ASP2138 also endorse the platform.

The report rated its irreplaceability as a 6 out of 6: platform reusability, verified collaborations, but net patents, licenses, and other intangible assets in 10-Q were only $6.524 million, with no disclosure of core patent remaining term, geographic coverage, or litigation status.

A tool borrowed by many big companies—is it a moat, or a skill that can be bypassed at any time?

Behind the 18-fold price-to-sales ratio, who is the market paying for?

For a biotech company still operating at a loss, both the price-to-earnings ratio (P/E) and the enterprise value multiple (EV/EBITDA) are useless. The P/E in the live_data shows 0 and earnings per share are -$2.16, so the report directly concluded the valuation is "unprofitable, not applicable."

Only a few usable anchors remain

According to the research report, the price-to-sales ratio (P/S) is 18.03 times, price-to-book ratio (P/B) is 4.31 times, return on equity (ROE) is -37.26%, and free cash flow yield is -7.90%. Calculated by market cap and P/S, market implied revenue of $120 million almost overlaps with FY 2025's $125.6 million, and today it rose nearly 16%, with the multiple only going higher**.

The scenario model in the report provides three levels of reference

Low scenario: 2029 revenue assumes $140 million to $190 million, with a P/S ratio of 3 to 4 times, corresponding to a market capitalization median of $590 million; Baseline scenario: $230 million to $340 million, 6 to 8 times, with a midpoint of $2.05 billion; High scenario: $450 million to $650 million, 9 to 11 times, with a midpoint of $5.6 billion.

The current $2.17 billion market cap is already above the benchmark scenario, meaning the market expects the market to expect revenue to rise from $125.6 million to $300 million, paired with a forward P/S ratio of over 7 times. Due to the lack of R&D expense guidance and project-level economic terms, the report clearly states that it cannot provide a credible DCF per-share value.

Cash is still enough to burn for a few years

On the cash flow side, the research report calculated cash, tradable bonds, and equity securities together, with $565 million as of June 30, 2026, a decrease of $158 million or 21.9% for half a year; The company's financial report only counts cash and tradable bonds, with $486.4 million in the same period, a significant drop from $610.8 million at the end of 2025.

The pace of burning money is accelerating

FY 2025 operating cash flow is -$177.5 million, free cash flow is -$135.1 million, and free cash flow is -$67.6 million in Q1 2026, compared to -$16.2 million in the same period last year; R&D expenses rose to $71.9 million in Q2, with a total net loss of $150.6 million in the first half.

The good news is that a $105 million settlement reached with Alexion over the U.S. Ultomiris franchise dispute was made in two installments of $52.5 million each, which are non-dilutive funds; The company directs cash between $420 million and $440 million by the end of 2026, enough to support operations through 2028, consistent with the research report's judgment of "burning cash but running for over two years."

So, is today's rally paying for a real-time fact, or is it an early payment for a registration study that hasn't even started yet? Our view is: early data positives have basically entered the stock price; the next thing to see is whether the late-stage trial design and FDA communication can be delivered, rather than speculating on the same data again.

During the commercial pilot phase, the market has already set prices for the next phase

The report classifies Xencor as a "commercialization pilot": it has passed the pure concept phase, with revenue sharing from Ultomiris and Monjuvi and collaborations with multiple pharmaceutical companies as validation, yet still far from mature pharma companies, with highly volatile revenue, a half-year loss of $150.6 million, and previous clinical projects lacking comparable efficacy data.

Today, XmAb819 fills one of these gaps. The company plans to launch single-drug registration studies in 2027 and is discussing accelerated approval pathways with the FDA. Looking at the moving averages, the stock price is well above the 50-day and 200-day moving averages, and the 50-day moving average itself is clearly above the 200-day line. The research report shows a 120.9% return over the past 12 months. The market is clearly pricing according to the "clinical realization period" rather than the "pilot phase", and this gap is precisely where the risks lie.

Partners are competitors, and the dual-resistance track is packed with giants

The first reference group listed in the report is Alexion/AstraZeneca, which is directly related to Ultomiris in the complement and rare disease fields; More accurately, Alexion is both a licensee of Xencor and a dispute opponent, having just settled a U.S. franchise dispute for $105 million, with overseas concessions continuing under the original agreement.

The second group is Monjuvi, Incyte and MorphoSys-related assets. The relapsed or refractory DLBCL market already has mature antibody and cell therapy options, but the research report did not provide data on Monjuvi's prescription volume, pricing, or market share.

The third group is Amgen, which serves as an important reference for bispecific antibodies and T-cell linker (T-cell engager) routes, directly targeting XmAb819, XmAb808, Xaluritamig, and Plamotamab; The fourth group, Bristol Myers Squibb, leverages mature tumor combinations and cell therapies to exert pressure on efficacy depth, physician trust, and payment coverage; The fifth group, established antibody companies like Regeneron, exert indirect pressure in the autoimmune market.

Xencor's relative advantages lie in its platform reuse between oncology and autoimmune diseases, rapid pipeline advancement, and the company's XmAb819, an ENPP3 x CD3 product, is even called a potential first-in-class innovation; Its disadvantage is that its scale, channels, and funding lag far behind the giants, and external collaborations dilute its economic exclusivity over individual projects while validating the technology.

The research report concluded that it is a "moderately strong platform-type moat."

Network effects are weak, scale effects are at a disadvantage, and regulatory capability is a qualification threshold, not a monopoly. Can a locksmith with a good key open his own store on a street full of giants? The 18.03x P/S requirement is precisely this execution.

The list of indications is long, but the market it serves cannot be counted

Potential indications range from ovarian cancer, renal cell carcinoma, prostate cancer, gastric cancer, DLBCL to NMOSD, gMG, aHUS, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. However, the report admits there is no Total Reachable Market (TAM), patient numbers, or unit price data; simply adding all indications together yields a beautiful but useless number.

What can be observed is only the lower limit

FY 2025 revenue is $125.6 million, with a mix of partnerships and other revenue. The analyst scenarios (non-company guidance) in the report are: Low scenario $120 million to $145 million in 2026, $140 million to $190 million in 2029; Baseline scenario: $145 million to $170 million in 2026, $230 million to $340 million in 2029; High scenario $180 million to $210 million in 2026, $450 million to $650 million in 2029.

It should be noted that the remaining $77.4 million in settlement revenue will be recognized in the third quarter, and the full-year 2026 figures will be raised all at once. When readers see full-year revenue "jump," don't misinterpret it as business acceleration. Market space narrative: before product-level sales data appears, it can only serve as an upside option, not a valuation base.

Six cards in the hands of the bulls

The logic of the bulls is not just imagination; it is built on several proven foundations, and today's ESMO data adds another layer:

▲ Bull Case

The bears are staring at six cracks

Bears do not deny that the data looks good; they question whether the attractive data can support the already elevated prices:

▼ Bear Case

After the data, the next test was fully booked

ESMO has already submitted its papers, and the upcoming months will be quite event-intensive, each potentially rewriting the valuation narrative:

•	Q3 Earnings Report: Yahoo estimates $77.4 million in settlement revenue will be recognized around November 4, with overstated revenue to be excluded, with a neutral to slightly bullish outlook
•	XmAb942 Ulcerative Colitis XENITH-UC Blinded Interim Analysis: Around the end of 2026, significant impact, direction to be determined
•	Plamotamab Rheumatoid Arthritis Phase Ib and XmAb657 Phase I update: Second half of 2026, moderate impact
•	Enrollment for XmAb541 monotherapy expansion completed: by the end of 2026, the target dose for combination therapy with XmAb808 is expected to reach in 2027
•	Results of communication with the FDA regarding the launch of the XmAb819 registration study: 2027 will determine whether the kidney cancer asset can go public

From a loss of 230 million to doubling in one year, the stock price is ahead of the fundamentals

FY 2024 was the year with the heaviest financial pressure: revenue of $110.5 million, net loss of $232.6 million, free cash flow of -$202.2 million. FY 2025 revenue grew 13.7% to $125.6 million, narrowing losses to $91.9 million, partly confirming expectations of "reduced losses and platform fulfillment," but operating cash flow remained -$177.5 million.

Quarterly revenue for 2025 fluctuated between $32.7 million, $43.6 million, and $21 million; in Q1 2026, it dropped to $4.5 million, with losses widening to $128.9 million; and in Q2, it rebounded to $51.2 million through settlement payments. Meanwhile, the stock price has risen 120.9% over the past 12 months. The market has been pricing in clinical and collaboration expectations in advance, and today's ESMO rally is just the steepest segment of this curve.

⚠️ Risk Notice • Early data samples were small, and later randomized controlled trials may not replicate the 45.5% response rate • Revenue depends on settlements, milestones, and the pace of collaborations, resulting in significant quarterly fluctuations • R&D investment is rising, cash consumption may be faster than historical averages, and refinancing is still possible • The bispecific antibody and TL1A tracks are packed with giants, and technological differentiation may not translate into market share • The short-term gains are huge, and after the positive data is digested, there is a risk of valuation drawdown

🟡 Neutral The kidney cancer data shows real progress, but most of the positive news has already been reflected in the stock price

💬 Discussion The data is real, but chasing at the high is not cost-effective; Real-time buy and sell positions, post XNCR on the official account for viewing.

Data source

•	Source: NextPick real-time snapshot + company earnings and SEC announcements + ESMO 2026 press release + mainstream financial media coverage.